STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
145
13F, latest reported quarter
What the filings say about CNXC
Insiders, 180 days
+$21.2K net bought
1 buyer
Concentrix insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Concentrix Corp insiders bought a net $21.2K of stock across 333 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
First Form 4 purchase or sale (code P or S) here by this insider on our record.
The trade is 216.3% of the 2,773,667 shares held after it.
No other insider sold within 30 days.
145 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider GBL Verwaltung S.A. sold about $133.5M of CNXC on Apr 29, 2026, the largest insider sale at the company on our record; 145 funds added in the latest 13F quarter.
1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Jul 12, 2022.
The trade is 2.8% of the 89,066 shares held after it.
1 other insider bought within 30 days.
145 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Valentine Andre S bought about $69.9K of CNXC on Apr 9, 2026; 1 other insider bought within 30 days and 145 funds added in the latest 13F quarter.
8 earlier Form 4 trades (code P or S) here by this insider (7 buys, 1 sale), the last on Jan 29, 2026.
-4.2% median (-1.4% mean) 90-day return after 7 previous buys.
The trade is 0.3% of the 357,382 shares held after it.
1 other insider bought within 30 days.
145 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Caldwell Christopher A bought about $27.0K of CNXC on Mar 26, 2026; 1 other insider bought within 30 days and 145 funds added in the latest 13F quarter.
Nobody has filed for crossing 5%. That is a fact, not missing data.
CNXC planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
CNXC mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Thompson MidCap Fund
$1.4M position · as of 2026-05-31
2.3%
Pzena Small Cap Value Fund
$1.9M position · as of 2026-05-31
2.0%
Pzena Mid Cap Value Fund
$1.7M position · as of 2026-05-31
1.7%
Invesco S&P Smallcap 600 Pure Value ETF
$3.7M position · as of 2026-07-31
1.3%
Thompson LargeCap Fund
$2.6M position · as of 2026-05-31
1.1%
S&P SmallCap 600 Pure Value Fund
$131.8K position · as of 2026-06-30
1.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Chris Caldwell
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$13.3M
$9.6M
$3.3M
-63%
-74%
2024
$11.6M
$2.3M
$2.3M
-57%
-74%
2023
$10.2M
$2.8M
$2.2M
-10%
-64%
2022
$8.6M
$2.2M
$1.7M
+17%
-28%
2021
$15.1M
$32.9M
$2.5M
+58%
+21%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $21.2K bought by insiders over 180 days, 145 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$10.0B
four quarters, 2025-09-01 to 2026-08-31
Revenue, TTM CNXC
FY Nov 2025
$9.8B
FY Nov 2024
$9.6B
FY Nov 2023
$7.1B
FY Nov 2022
$6.3B
FY Nov 2021
$5.6B
Aug 2026
$2.5B
May 2026
$2.5B
Feb 2026
$2.5B
Nov 2025
$2.6B
Aug 2025
$2.5B
May 2025
$2.4B
Feb 2025
$2.4B
Nov 2024
$2.4B
At each fiscal year end
Single quarter
Net margin, TTM
-24.0%
net income over revenue, 2025-09-01 to 2026-08-31
Net margin, TTM CNXC
FY Nov 2025
-13.0%
FY Nov 2024
+2.6%
FY Nov 2023
+4.4%
FY Nov 2022
+6.9%
FY Nov 2021
+7.3%
Aug 2026
-40.3%
May 2026
+2.2%
Feb 2026
+0.9%
Nov 2025
-57.9%
Aug 2025
+3.5%
May 2025
+1.7%
Feb 2025
+3.0%
Nov 2024
+4.7%
At each fiscal year end
Single quarter
Free cash flow, TTM
$575.0M
operating cash flow minus capex, 2025-09-01 to 2026-08-31
Free cash flow, TTM CNXC
FY Nov 2025
$572.5M
FY Nov 2024
$428.7M
FY Nov 2023
$497.5M
FY Nov 2022
$460.7M
FY Nov 2021
$365.1M
Aug 2026
$221.2M
May 2026
$209.7M
Feb 2026
-$137.1M
Nov 2025
$281.2M
Aug 2025
$159.7M
May 2025
$180.7M
Feb 2025
-$49.2M
Nov 2024
$224.5M
At each fiscal year end
Single quarter
Debt to equity
2.47x
long-term 2026-08-31 plus current 2026-08-31; equity 2026-08-31
Debt to equity CNXC
FY Nov 2025
1.69x
FY Nov 2024
1.17x
FY Nov 2023
1.19x
FY Nov 2022
0.83x
FY Nov 2021
0.31x
Aug 2026
2.47x
May 2026
1.70x
Feb 2026
1.70x
Nov 2025
1.69x
Aug 2025
1.11x
May 2025
1.14x
Feb 2025
1.22x
Nov 2024
1.17x
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.18x
TTM operating cash flow over long-term 2026-08-31 plus current 2026-08-31
Cash flow to debt CNXC
FY Nov 2025
0.17x
FY Nov 2024
0.14x
FY Nov 2023
0.14x
FY Nov 2022
0.27x
FY Nov 2021
0.64x
Aug 2026
0.18x
May 2026
0.16x
Feb 2026
0.15x
Nov 2025
0.17x
Aug 2025
0.15x
May 2025
0.15x
Feb 2025
0.15x
Nov 2024
0.14x
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-78.2%
TTM net income over average of 2025-08-31 and 2026-08-31
Return on equity CNXC
FY Nov 2025
-37.7%
FY Nov 2024
+6.1%
FY Nov 2023
+9.2%
FY Nov 2022
+16.4%
FY Nov 2021
+16.5%
Aug 2026
-78.2%
May 2026
-37.7%
Feb 2026
-38.9%
Nov 2025
-37.7%
Aug 2025
+7.4%
May 2025
+5.9%
Feb 2025
+6.6%
Nov 2024
+6.1%
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-22.1%
TTM net income over average of 2025-08-31 and 2026-08-31
Return on assets CNXC
FY Nov 2025
-11.2%
FY Nov 2024
+2.1%
FY Nov 2023
+3.3%
FY Nov 2022
+7.4%
FY Nov 2021
+7.9%
Aug 2026
-22.1%
May 2026
-11.5%
Feb 2026
-11.8%
Nov 2025
-11.2%
Aug 2025
+2.6%
May 2025
+2.0%
Feb 2025
+2.2%
Nov 2024
+2.1%
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital CNXC
FY Nov 2025
n/a
FY Nov 2024
+5.8%
FY Nov 2023
+6.2%
FY Nov 2022
+9.8%
FY Nov 2021
+13.5%
Aug 2026
n/a
May 2026
n/a
Feb 2026
n/a
Nov 2025
n/a
Aug 2025
+5.8%
May 2025
+5.9%
Feb 2025
+5.8%
Nov 2024
+5.8%
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-24.0%
operating income (EBIT proxy) over average of 2025-08-31 and 2026-08-31 minus current liabilities
Return on capital employed CNXC
FY Nov 2025
-9.9%
FY Nov 2024
+5.8%
FY Nov 2023
+8.3%
FY Nov 2022
+13.3%
FY Nov 2021
+13.9%
Aug 2026
-24.0%
May 2026
-11.1%
Feb 2026
-10.6%
Nov 2025
-9.9%
Aug 2025
+5.9%
May 2025
+5.9%
Feb 2025
+6.0%
Nov 2024
+5.8%
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing CNXC
FY Nov 2025
n/a
FY Nov 2024
12.15x
FY Nov 2023
16.46x
FY Nov 2022
14.80x
FY Nov 2021
21.59x
Aug 2026
n/a
May 2026
n/a
Feb 2026
n/a
Nov 2025
n/a
Aug 2025
11.18x
May 2025
15.42x
Feb 2025
11.35x
Nov 2024
12.15x
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$6.1B
market value at close 2026-10-26 on 2026-09-30 shares, plus long-term 2026-08-31 plus current 2026-08-31, minus cash 2026-08-31
Enterprise value CNXC
FY Nov 2025
$6.6B
FY Nov 2024
$7.4B
FY Nov 2023
$10.9B
FY Nov 2022
$8.4B
FY Nov 2021
$9.3B
Aug 2026
$6.0B
May 2026
$6.1B
Feb 2026
$6.5B
Nov 2025
$6.6B
Aug 2025
$7.8B
May 2025
$8.1B
Feb 2025
$7.5B
Nov 2024
$7.4B
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+29.4%
TTM free cash flow over market value at close 2026-10-26
FCF yield CNXC
FY Nov 2025
+25.4%
FY Nov 2024
+14.7%
FY Nov 2023
+7.9%
FY Nov 2022
+7.3%
FY Nov 2021
+4.2%
Aug 2026
+31.3%
May 2026
+29.8%
Feb 2026
+24.0%
Nov 2025
+25.4%
Aug 2025
+15.5%
May 2025
+13.6%
Feb 2025
+16.6%
Nov 2024
+14.7%
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing CNXC
FY Nov 2025
n/a
FY Nov 2024
n/a
FY Nov 2023
n/a
FY Nov 2022
1.96x
FY Nov 2021
0.15x
Aug 2026
n/a
May 2026
n/a
Feb 2026
n/a
Nov 2025
n/a
Aug 2025
0.20x
May 2025
n/a
Feb 2025
n/a
Nov 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
CNXC ranks highest on insider conviction (64th percentile) and institutional and government (61st), and lowest on profitability (18th), among Services peers.
Profitability
18
Inputs
Return on equity-78.2% · 14 pct, sector of 207
Return on assets-22.1% · 25 pct, sector of 269
Return on invested capitalpre-tax loss, no effective tax rate to apply
Return on capital employed-24.0% · 17 pct, sector of 203
Financial health
28
Inputs
Debt to equity2.47x · 10 pct, sector of 228
Cash flow to debt0.18x · 45 pct, sector of 199
Growth
39
Inputs
Revenue growth, YoY+2.2% · 39 pct, sector of 341
Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
64
Inputs
Net Form 4 buying (codes P and S), 180d$21K · 72 pct, sector of 174
Insider buyers, 180d1 · 57 pct, sector of 179
Institutional and government
61
Inputs
Funds adding, latest quarter145 · 61 pct, sector of 243
Congress net buyers, 365dno Congress trades in 365 days
Federal contracts, 180dno federal contracts in 180 days
Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
21
Inputs
Short interest, % of float+18.9% · 6 pct, sector of 383
Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
New text in Risk Factors, latest 10-K+15.2% · 37 pct, sector of 227
1 not measured: US patents
US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
CNXC filings, in plain words
Are Concentrix insiders buying or selling CNXC?
In the 180 days to 2026-10-28, Concentrix insiders were net buyers, a net $21.2K across purchases and sales reported on Form 4, by 1 buyer.
Read the full summary
In the 180 days to 2026-10-28, Concentrix insiders were net buyers of CNXC, a net $21.2K across purchases and sales reported on Form 4 by 1 buyer. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
No password to create and no card required. We store your email address, your watchlist and your preferences, nothing else.
PRIVACY & COOKIES
We track filings, not you.
Essential cookies keep you signed in and remember this choice.
Google Analytics 4 and Microsoft Clarity load only if you allow them here; they
count visits and record how pages are used. We run no advertising and never sell
data. Details in the privacy policy. Change this any time
via "Cookie settings" in the footer.